Masonic Cancer Center, University of Minnesota | Strategic Alliance Partners

Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.

Douglas Yee, MD, discusses neoadjuvant datopotamab deruxtecan in early-stage breast cancer

Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.

Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.

Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.

Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.

Marie Hu, MD, discusses considerations for the use of CAR T-cell therapy and bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma.

Jeremy Allred, MD, details current and emerging treatments for patients with myelodysplastic syndrome, highlighting recent key data updates.

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.

Sanjal Desai, MD, expands on the safety, efficacy, and sequencing of BTK inhibitors and venetoclax-based regimens in chronic lymphocytic leukemia.

Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.

TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.

Emmanuel Antonarakis, MD, discusses community enrollment in the ECLIPSE trial in prostate cancer.

Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.

Emmanuel Antonarakis, MD, discusses the significance of TALPRO-3, EVOPAR, and AMPLITUDE trials on the metastatic prostate cancer treatment paradigm.

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss the ins and outs of clinical trial partnerships between community and academic cancer centers.

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss enrollment to the ECLIPSE trial in community and academic cancer center settings.

Kiara Ellis, MSW, details community outreach and engagement conversations centered around key matters affecting NCI-designated cancer centers.

Veronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.